EpiCure is pioneering next-generation epigenetic cancer therapies for hematologic malignancies, aiming for significantly improved efficacy and a 100-fold reduction in toxicity compared to conventional treatments. With over 750,000 patients affected globally each year, the team is addressing a pressing need for safer and more effective therapeutic options.
Endowed with €500,000, the m⁴ Award supports academic research projects with strong translational potential. The funding will drive key preclinical studies, laying the groundwork for first-in-human trials and an upcoming spin-off from LMU.
This award highlights not only the scientific strength of EpiCure’s approach but also the broader mission of the LMU Innovation Incubator: to help transform high-impact research into real-world innovation.
Congratulations to the EpiCure team on this remarkable achievement! we look forward to following your journey and the difference you will make in the field of biotech.
Check this out!